GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,393.00p
   
  • Change Today:
    -6.50p
  • 52 Week High: 1,812.50p
  • 52 Week Low: 1,264.00p
  • Currency: UK Pounds
  • Shares Issued: 4,105.52m
  • Volume: 978,104
  • Market Cap: £57,190m
  • RiskGrade: 129

GSK cancer treatment meets trial endpoint

By Frank Prenesti

Date: Friday 02 Dec 2022

LONDON (ShareCast) - (Sharecast News) - GSK on Friday unveiled positive headline results from a Phase 3 trial of its Jemperli endometrial cancer drug.


The company said Jemperli met its primary endpoint of investigator-assessed progression-free survival (PFS) and showed a "statistically significant and clinically meaningful benefit".

Endometrial cancer is found in the inner lining of the uterus, known as the endometrium. It is the most common gynaecologic cancer in the US and the second most common gynaecologic cancer globally.

Approximately 15-20% of women with endometrial cancer will be diagnosed with advanced disease at the time of diagnosis.

Reporting by Frank Prenesti for Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,393.00p
Change Today -6.50p
% Change -0.46 %
52 Week High 1,812.50p
52 Week Low 1,264.00p
Volume 978,104
Shares Issued 4,105.52m
Market Cap £57,190m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
37.77% below the market average37.77% below the market average37.77% below the market average37.77% below the market average37.77% below the market average
41.67% above the sector average41.67% above the sector average41.67% above the sector average41.67% above the sector average41.67% above the sector average
Price Trend
9.44% below the market average9.44% below the market average9.44% below the market average9.44% below the market average9.44% below the market average
27.66% above the sector average27.66% above the sector average27.66% above the sector average27.66% above the sector average27.66% above the sector average
Income
72.40% above the market average72.40% above the market average72.40% above the market average72.40% above the market average72.40% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
39.7% below the market average39.7% below the market average39.7% below the market average39.7% below the market average39.7% below the market average
37.5% below the sector average37.5% below the sector average37.5% below the sector average37.5% below the sector average37.5% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 14
Sell 3
Strong Sell 1
Total 24
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 15-May-25 20-Feb-25
Paid 10-Jul-25 10-Apr-25
Amount 16.00p 16.00p

Trades for 13-May-2025

Time Volume / Share Price
09:49 213 @ 1,393.20p
09:49 290 @ 1,393.00p
09:49 140 @ 1,393.00p
09:49 0 @ 1,393.50p
09:49 1 @ 1,393.50p

GSK Key Personnel

CEO Emma Walmsley

Top of Page